Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria
dc.authorid | 0000-0002-4563-7027 | en_US |
dc.contributor.author | Volkan İnce | |
dc.contributor.author | Sami Akbulut | |
dc.contributor.author | Emrah Otan | |
dc.contributor.author | Veysel Ersan | |
dc.contributor.author | Serdar Karakaş | |
dc.contributor.author | Tolga Tevfik Şahin | |
dc.contributor.author | Brian I Carr | |
dc.contributor.author | Adil Baskiran | |
dc.contributor.author | Emine Şamdancı | |
dc.contributor.author | Harika Gözükara Bağ | |
dc.contributor.author | Cemalettin Koç | |
dc.contributor.author | Sertaç Usta | |
dc.contributor.author | Fatih Özdemir | |
dc.contributor.author | Bora Barut | |
dc.contributor.author | Fatih Gönültas | |
dc.contributor.author | Barış Sarıcı | |
dc.contributor.author | Koray Kutluturk | |
dc.contributor.author | Murat Sait Dogan | |
dc.contributor.author | Dinçer Özgör | |
dc.contributor.author | Mustafa Dikilitaş | |
dc.contributor.author | Murat Harputluoglu | |
dc.contributor.author | Murat Aladağ | |
dc.contributor.author | Ramazan Kutlu | |
dc.contributor.author | Ilknur Varol | |
dc.contributor.author | Abuzer Dirican | |
dc.contributor.author | Cemalettin Aydın | |
dc.contributor.author | Burak Işık | |
dc.contributor.author | Cengiz Ara | |
dc.contributor.author | Cüneyt Kayaalp | |
dc.contributor.author | Şükrü Emre | |
dc.contributor.author | Sezai Yılmaz | |
dc.date.accessioned | 2022-05-06T07:16:09Z | |
dc.date.available | 2022-05-06T07:16:09Z | |
dc.date.issued | 2020 | en_US |
dc.department | MTÖ Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.description.abstract | Survival was examined from a Turkish liver transplant center of patients with HCC, to identify prognostic factors. Data from 215 patients who underwent predominantly live donor liver transplant for HCC at our institute over 12 years were included in the study and prospectively recorded. They were 152 patients within and 63 patients beyond Milan criteria. Patients beyond Milan criteria were divided into two groups according to presence or absence of tumor recurrence. Recurrence-associated factors were analyzed. These factors were then applied to the total cohort for survival analysis. We identified four factors, using multivariate analysis, that were significantly associated with tumor recurrence. These were maximum tumor diameter, degree of tumor differentiation, and serum AFP and GGT levels. A model that included all four of these factors was constructed, the ‘Malatya criteria.’ Using these Malatya criteria, we estimated DFS and cumulative survival, for patients within and beyond these criteria, and found statistically significant differences with improved survival in patients within Malatya criteria of 1, 5, and 10-year overall survival rates of 90.1%, 79.7%, and 72.8% respectively, which compared favorably with other extra-Milan extended criteria. Survival of our patients within the newly defined Malatya criteria compared favorably with other extra-Milan extended criteria and highlight the usefulness of serum AFP and GGT levels in decision-making. | en_US |
dc.identifier.citation | Ince, V., Akbulut, S., Otan, E., Ersan, V., Karakas, S., Sahin, T. T., ... & Yilmaz, S. (2020). Liver transplantation for hepatocellular carcinoma: Malatya experience and proposals for expanded criteria. Journal of Gastrointestinal Cancer, 51(3), 998-1005. | en_US |
dc.identifier.doi | 10.1007/s12029-020-00424-w | |
dc.identifier.endpage | 1005 | en_US |
dc.identifier.startpage | 998 | en_US |
dc.identifier.uri | https://doi.org/10.1007/s12029-020-00424-w | |
dc.identifier.uri | https://hdl.handle.net/20.500.12899/1067 | |
dc.identifier.volume | 51 | en_US |
dc.institutionauthor | Aladağ, Murat | |
dc.language.iso | en | en_US |
dc.publisher | Murat Aladag | en_US |
dc.relation.ispartof | Journal of Gastrointestinal Cancer | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Hepatic | en_US |
dc.subject | Malignancy | en_US |
dc.subject | Live donor | en_US |
dc.subject | Malatya criteria | en_US |
dc.title | Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria | en_US |
dc.type | Article | en_US |
Dosyalar
Orijinal paket
1 - 1 / 1
Küçük Resim Yok
- İsim:
- Ince2020_Article_LiverTransplantationForHepatoc.pdf
- Boyut:
- 611.37 KB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Makale Dosyası
Lisans paketi
1 - 1 / 1
Küçük Resim Yok
- İsim:
- license.txt
- Boyut:
- 1.44 KB
- Biçim:
- Item-specific license agreed upon to submission
- Açıklama: